Back to top
more

BioLife Solutions (BLFS)

(Real Time Quote from BATS)

$21.95 USD

21.95
135,916

-0.93 (-4.07%)

Updated Aug 7, 2024 03:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should You Buy BioLife (BLFS) Ahead of Earnings?

by Zacks Equity Research

BioLife (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Moving Average Crossover Alert: BioLife Solutions

by Zacks Equity Research

BioLife Solutions, Inc. (BLFS) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

BioLife (BLFS) Catches Eye: Stock Jumps 12.1%

by Zacks Equity Research

BioLife (BLFS) saw a big move last session, as its shares jumped more than 12% on the day, amid huge volumes.

CytoDyn (CYDY) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

On CytoDyn's (CYDY) upcoming earnings call, investor focus will be on the updates related to its CCR5 antagonist candidate, leronlimab, which is being developed for multiple therapeutic indications.

Why Earnings Season Could Be Great for BioLife Solutions (BLFS)

by Zacks Equity Research

BioLife Solutions (BLFS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Aurora Cannabis (ACB) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Aurora Cannabis' (ACB) fiscal third-quarter results likely to reflect solid prospects in the Canadian market.

What's in the Cards for SmileDirectClub's (SDC) Q1 Earnings?

by Zacks Equity Research

SmileDirectClub's (SDC) first-quarter performance is likely to reflect benefits from international presence and product development.

Daqo New Energy (DQ) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Our proven model does not conclusively predict an earnings beat for Daqo New Energy (DQ) this season.

Trina Mukherjee headshot

Medical Products Industry Outlook: Prospects Seem Promising

by Trina Mukherjee

Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.

BioLife Solutions (BLFS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

BioLife (BLFS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioLife Solutions (BLFS) to Report Q1 Results: Wall Street Expects Earnings Growth

by Zacks Equity Research

BioLife (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Invest in Stryker (SYK) Stock Right Now

by Zacks Equity Research

Stryker's (SYK) strong guidance for the first quarter of 2019 buoys optimism in the stock.

Nabaparna Bhattacharya headshot

Medical Products Industry Gathering Steam: 3 Stocks to Buy

by Nabaparna Bhattacharya

The Medical Products market is gaining traction from a firm exposure to robotics, medical mechatronics and the bipartisan two-year suspension of a 2.3% excise tax on MedTech manufacturers.

BioLife (BLFS) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

BioLife (BLFS) is likely to gain from solid segmental revenues in Q3.

What's in Store for AmerisourceBergen (ABC) in Q4 Earnings?

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to be driven by its core Pharmaceutical Distribution business despite a competitive industry.

What's in Store for Quidel (QDEL) This Earnings Season?

by Zacks Equity Research

Strong growth in Cardiac Immunoassay segment's revenues is likely to drive Quidel's (QDEL) top line in Q3.

Can Solid European Sales Boost Inogen (INGN) in Q3 Earnings?

by Zacks Equity Research

Strong performance in Europe is likely to boost Inogen's (INGN) top line in the third quarter. However, the decline in rental revenues is a concern.

BioLife Solutions (BLFS) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

BioLife (BLFS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioLife Solutions Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

BioLife Solutions has been struggling lately, but the selling pressure may be coming to an end soon.

    Is BioLife Solutions (BLFS) Stock Outpacing Its Medical Peers This Year?

    by Zacks Equity Research

    Is (BLFS) Outperforming Other Medical Stocks This Year?

      The Zacks Analyst Blog Highlights: Turtle Beach, BioLife Solutions, IntriCon and Medifast

      by Zacks Equity Research

      The Zacks Analyst Blog Highlights: Turtle Beach, BioLife Solutions, IntriCon and Medifast

        Nitish Marwah headshot

        Trump's Approval Rating Buoy Wall Street: 4 Top Gainers

        by Nitish Marwah

        Trump's pro-growth agenda has worked wonders for the economy as a whole.

          Canopy Growth (CGC) Jumps: Stock Rises 7.4%

          by Zacks Equity Research

          Canopy Growth (CGC) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

            Nalak Das headshot

            Bull Run to Continue in Rest of 2018: 5 Terrific Growth Picks

            by Nalak Das

            Strong economic fundamentals of the United States suggest that the recent volatility may be transitory and that markets will continue their uptrend.

              Medtronic (MDT) Surges: Stock Moves 5.7% Higher

              by Zacks Equity Research

              Medtronic (MDT) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.